Eyepoint’s Phase 3 trial for age‑related blindness treatment fails primary endpoint, jeopardizing approval plans

Eyepoint announced that its Phase 3 trial of the experimental drug Duravyu for a common cause of age‑related blindness did not meet its primary endpoint. Patients receiving the investigational therapy with less frequent injections failed to maintain vision compared with the standard treatment.

The failure puts the company’s plan to seek regulatory approval in doubt, as the results fell short of expectations.

The newsletter also highlighted other industry news, such as a win for Amylyx and Novartis deciding not to pursue reimbursement in Canada for a rare kidney disease drug, but the Eyepoint setback was the primary focus.